🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Humacyte, Inc. (HUMA)
NASDAQ: HUMA · Real-Time Price · USD
0.4454
-0.0971 (-17.90%)
At close: Nov 20, 2026, 4:00 PM EST
0.4613
+0.0159 (3.57%)
After-hours: Nov 20, 2026, 7:59 PM EST

Humacyte Statistics

Total Valuation

Humacyte has a market cap or net worth of $123.73 million. The enterprise value is $126.39 million.

Market Cap123.73M
Enterprise Value 126.39M

Important Dates

The last earnings date was Tuesday, November 10, 2026, before market open.

Earnings Date Nov 10, 2026
Ex-Dividend Date n/a

Share Statistics

Humacyte has 277.80 million shares outstanding. The number of shares has increased by 56.80% in one year.

Current Share Class 277.80M
Shares Outstanding 277.80M
Shares Change (YoY) +56.80%
Shares Change (QoQ) +18.62%
Owned by Insiders (%) 3.60%
Owned by Institutions (%) 19.79%
Float 250.79M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 51.64
Forward PS 8.21
PB Ratio 6.85
P/TBV Ratio 6.85
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 52.75
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.34, with a Debt / Equity ratio of 3.72.

Current Ratio 3.34
Quick Ratio 3.01
Debt / Equity 3.72
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -10.90

Financial Efficiency

Return on equity (ROE) is -1,423.62% and return on invested capital (ROIC) is -104.20%.

Return on Equity (ROE) -1,423.62%
Return on Assets (ROA) -87.31%
Return on Invested Capital (ROIC) -104.20%
Return on Capital Employed (ROCE) -108.70%
Weighted Average Cost of Capital (WACC) 16.47%
Revenue Per Employee $13,022
Profits Per Employee -$515,016
Employee Count184
Asset Turnover 0.02
Inventory Turnover 6.87

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -61.93% in the last 52 weeks. The beta is 2.68, so Humacyte's price volatility has been higher than the market average.

Beta (5Y) 2.68
52-Week Price Change -61.93%
50-Day Moving Average 0.49
200-Day Moving Average 0.77
Relative Strength Index (RSI) 44.84
Average Volume (20 Days) 5,012,613

Short Selling Information

The latest short interest is 28.07 million, so 10.11% of the outstanding shares have been sold short.

Short Interest 28.07M
Short Previous Month 30.25M
Short % of Shares Out 10.11%
Short % of Float 11.19%
Short Ratio (days to cover) 4.56

Income Statement

In the last 12 months, Humacyte had revenue of $2.40 million and -$94.76 million in losses. Loss per share was -$0.42.

Revenue2.40M
Gross Profit -80.10M
Operating Income -109.59M
Pretax Income -94.76M
Net Income -94.76M
EBITDA -102.50M
EBIT -109.59M
Loss Per Share -$0.42
Full Income Statement

Balance Sheet

The company has $64.52 million in cash and $67.18 million in debt, with a net cash position of -$2.66 million or -$0.01 per share.

Cash & Cash Equivalents 64.52M
Total Debt 67.18M
Net Cash -2.66M
Net Cash Per Share -$0.01
Equity (Book Value) 18.06M
Book Value Per Share 0.07
Working Capital 57.92M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$88.26 million and capital expenditures -$318,000, giving a free cash flow of -$88.58 million.

Operating Cash Flow -88.26M
Capital Expenditures -318,000
Depreciation & Amortization 7.09M
Net Borrowing 38.79M
Free Cash Flow -88.58M
FCF Per Share -$0.32
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin -4,573.71%
Pretax Margin -3,955.05%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Humacyte does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield -56.80%
Shareholder Yield n/a
Earnings Yield -94.79%
FCF Yield -71.59%

Analyst Forecast

The average price target for Humacyte is $1.64, which is 268.66% higher than the current price. The consensus rating is "Buy".

Price Target $1.64
Price Target Difference 268.66%
Analyst Consensus Buy
Analyst Count 6
Revenue Growth Forecast (3Y) 283.41%
EPS Growth Forecast (3Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a
Graham Formula Value n/a
Graham Formula Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Humacyte has an Altman Z-Score of -10 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -10
Piotroski F-Score 3